RegenXBio AI Stock Analysis
RegenXBio (RB0) AI Stock Analysis
RegenXBio
(Frankfurt:RB0)
No summary available
RegenXBio (RB0) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 505.18M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,604
- Price to Earnings (P/E)
- -2.4
- Beta (1Y)
- 1.46
- Revenue Growth
- -10.99%
- EPS Growth
- 10.99%
- Country
- Germany
- Employees
- 371
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
RegenXBio Business Overview & Revenue Model
Company Description
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the...
RegenXBio Earnings Call Summary
The call was strongly optimistic, with extensive progress across sura-vec and RGX-202, encouraging clinical and biomarker data, significant AbbVie milestone funding, a cash runway extending beyond late 2027 milestones, and preparations for potential commercialization. The principal negatives were the unresolved regulatory path for RGX-121, the expiration of U.S. ZOLGENSMA intellectual property, and the fact that major sura-vec and RGX-202 regulatory milestones remain pending.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
REGENXBIO expects top line results from both ATMOSPHERE and ASCENT this quarter, followed by global regulatory submissions in 2027; RGX-202 preparations are underway for a full BLA submission in the first quarter of 2027 under the accelerated approval pathway, supporting potential approval in the U.S. in the second half of 2027, while the AFFINITY RISE study is expected to initiate in the first half of 2027 and enroll approximately 100 patients with a 2:1 active to placebo randomization. The company expects its RGX-202 BLA to include safety data from more than 60 patients, expects pre-BLA meeting minutes about 30 days post the meeting, expects BLA acceptance about 2 months after submission, and expects a review process through the next 6 months. For wet AMD, the goal is at least a 50% reduction in treatment burden with a meaningful proportion of those patients not needing any injection, and cash runway is late into fourth quarter of 2027.
RegenXBio Risk Analysis
RegenXBio disclosed 54 risk factors in its most recent earnings report. RegenXBio reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksRegenXBio Peers Comparison
Overall Rating
IRD53Neutral
FDMT45Neutral
RCKT42Neutral
SLDB42Neutral
NGNE39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 53Neutral | $384.68M | -2.60 | 9999.00% | ― | -45.92% | 10.87% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | $675.64M | -4.38 | -47.06% | ― | 79952.50% | 29.07% | |
| 42Neutral | $256.82M | -16.43 | -5.34% | ― | ― | 93.49% | |
| 42Neutral | $763.42M | -3.82 | -67.78% | ― | ― | 28.59% | |
| 39Underperform | $495.37M | -4.30 | -44.36% | ― | ― | -25.59% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:RB0 | RegenXBio Inc. | 7.14 | -2.76 | -27.86% | |
| IRD | Opus Genetics, Inc. | 3.98 | 2.24 | 128.74% | |
| NGNE | Neurogene Inc. | 23.93 | 1.47 | 6.54% | |
| RCKT | Rocket Pharma | 2.30 | -0.74 | -24.34% | |
| SLDB | Solid Biosciences | 6.84 | 2.50 | 57.60% | |
| FDMT | 4D Molecular Therapeutics, Inc. | 12.23 | 1.28 | 11.69% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
